Sector News

AstraZeneca appoints Professor Nazneen Rahman to its Board

June 2, 2017
Life sciences

AstraZeneca announced that, effective 1 June 2017, the Board has appointed Professor Nazneen Rahman as a Non-Executive Director of AstraZeneca PLC. On appointment, Professor Rahman also becomes a member of the Science Committee.

Professor Nazneen Rahman is Head of the Division of Genetics and Epidemiology at the Institute of Cancer Research (ICR), London; Head of the Cancer Genetics Unit at the Royal Marsden NHS Foundation Trust; and Director of the TGL clinical gene testing laboratory at the ICR. She qualified in medicine from Oxford University and holds a PhD in molecular genetics, according to AstraZeneca.

Professor Rahman’s research harnesses her scientific and clinical expertise to identify and clinically implement human disease genes. She has a strong focus on cancer predisposition genes, in which she is an internationally-recognised expert and has discovered many such genes during her career, particularly for breast, ovarian and childhood cancers.

Elected as a Fellow of the Academy of Medical Sciences in 2010, Professor Rahman is a member of the scientific advisory boards of Genomics plc and the Centre for Molecular Medicine Norway, as well as the advisory board of Wellcome Open Research.

Professor Rahman has a strong commitment to open science and science communication and has garnered numerous awards, including a CBE in the 2016 Queen’s birthday honours in recognition of her contribution to medical sciences.

Leif Johansson, Chairman of AstraZeneca, said: “We are delighted to welcome Professor Rahman to our Board and Science Committee. She brings world-renowned expertise in genetic research with a focus on cancer, which is a strategic therapy area for our business.”

In relation to Professor Rahman’s appointment, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority’s Listing Rules.

Source: The Financial

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.